March 15, 2018 | Yokneam-based Israeli startup PixCell, which develops, manufactures, and markets portable medical diagnostic products for simple blood sampling and analysis, announced that it was awarded a 2.5 million Euro (approximately $3 million) grant to “accelerate commercialization of its product the HemoScreen.” The funding will serve to further test the product, the company said. The Hemoscreen is a portable blood analyzer that performs common test including a blood count with results within 5 minutes, PixCell says. The product is CE marked and expected to be FDA cleared during 2018.